

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Cardiology

**ESPS manuscript NO:** 25170

**Title:** Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure

**Reviewer's code:** 00227470

**Reviewer's country:** Netherlands

**Science editor:** Xue-Mei Gong

**Date sent for review:** 2016-02-26 14:16

**Date reviewed:** 2016-03-03 18:41

| CLASSIFICATION   | LANGUAGE EVALUATION  | SCIENTIFIC MISCONDUCT                          | CONCLUSION   |
|--|--|--|--|
| <input type="checkbox"/> Grade A: Excellent            | <input checked="" type="checkbox"/> Grade A: Priority publishing     | Google Search:                                 | <input type="checkbox"/> Accept                        |
| <input checked="" type="checkbox"/> Grade B: Very good | <input type="checkbox"/> Grade B: Minor language polishing           | <input type="checkbox"/> The same title        | <input type="checkbox"/> High priority for publication |
| <input type="checkbox"/> Grade C: Good                 | <input type="checkbox"/> Grade C: A great deal of language polishing | <input type="checkbox"/> Duplicate publication | <input type="checkbox"/> Rejection                     |
| <input type="checkbox"/> Grade D: Fair                 | <input type="checkbox"/> Grade D: Rejected                           | <input checked="" type="checkbox"/> No         | <input checked="" type="checkbox"/> Minor revision     |
| <input type="checkbox"/> Grade E: Poor                 |  | BPG Search:                                    | <input type="checkbox"/> Major revision                |
|  |  | <input type="checkbox"/> The same title        |  |
|  |  | <input type="checkbox"/> Duplicate publication |  |
|  |  | <input type="checkbox"/> Plagiarism            |  |
|  |  | <input checked="" type="checkbox"/> No         |  |

## COMMENTS TO AUTHORS

Thank you for this concise overview of studies on PDE inhibitors in end-stage heart failure. The idea of combining PDE inhibitor with BB therapy is attractive and clinically tried (see Constantinescu et al, Eur J Heart Fail 2014). As the authors correctly point out, more research is needed. I ask the authors to cite the paper I mentioned here and this would be my only comment.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Cardiology

**ESPS manuscript NO:** 25170

**Title:** Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure

**Reviewer's code:** 00100945

**Reviewer's country:** Israel

**Science editor:** Xue-Mei Gong

**Date sent for review:** 2016-02-26 14:16

**Date reviewed:** 2016-03-16 04:52

| CLASSIFICATION   | LANGUAGE EVALUATION  | SCIENTIFIC MISCONDUCT                          | CONCLUSION   |
|--|--|--|--|
| <input checked="" type="checkbox"/> Grade A: Excellent | <input checked="" type="checkbox"/> Grade A: Priority publishing     | Google Search:                                 | <input checked="" type="checkbox"/> Accept             |
| <input type="checkbox"/> Grade B: Very good            | <input type="checkbox"/> Grade B: Minor language polishing           | <input type="checkbox"/> The same title        | <input type="checkbox"/> High priority for publication |
| <input type="checkbox"/> Grade C: Good                 | <input type="checkbox"/> Grade C: A great deal of language polishing | <input type="checkbox"/> Duplicate publication | <input type="checkbox"/> Rejection                     |
| <input type="checkbox"/> Grade D: Fair                 | <input type="checkbox"/> Grade D: Rejected                           | <input checked="" type="checkbox"/> No         | <input type="checkbox"/> Minor revision                |
| <input type="checkbox"/> Grade E: Poor                 |  | BPG Search:                                    | <input type="checkbox"/> Major revision                |
|  |  | <input type="checkbox"/> The same title        |  |
|  |  | <input type="checkbox"/> Duplicate publication |  |
|  |  | <input type="checkbox"/> Plagiarism            |  |
|  |  | <input checked="" type="checkbox"/> No         |  |

## COMMENTS TO AUTHORS

Very nice review. A little too long. NO special comments

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Cardiology

**ESPS manuscript NO:** 25170

**Title:** Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure

**Reviewer's code:** 00227375

**Reviewer's country:** Japan

**Science editor:** Xue-Mei Gong

**Date sent for review:** 2016-02-26 14:16

**Date reviewed:** 2016-03-16 18:49

| CLASSIFICATION                              | LANGUAGE EVALUATION  | SCIENTIFIC MISCONDUCT                          | CONCLUSION   |
|---|--|--|--|
| <input type="checkbox"/> Grade A: Excellent | <input type="checkbox"/> Grade A: Priority publishing                | Google Search:                                 | <input type="checkbox"/> Accept                        |
| <input type="checkbox"/> Grade B: Very good | <input type="checkbox"/> Grade B: Minor language polishing           | <input type="checkbox"/> The same title        | <input type="checkbox"/> High priority for publication |
| <input type="checkbox"/> Grade C: Good      | <input type="checkbox"/> Grade C: A great deal of language polishing | <input type="checkbox"/> Duplicate publication | <input type="checkbox"/> Rejection                     |
| <input type="checkbox"/> Grade D: Fair      | <input type="checkbox"/> Grade D: Rejected                           | <input type="checkbox"/> Plagiarism            | <input type="checkbox"/> Minor revision                |
| <input type="checkbox"/> Grade E: Poor      |  | <input type="checkbox"/> No                    | <input type="checkbox"/> Major revision                |
|   |  | BPG Search:                                    |  |
|   |  | <input type="checkbox"/> The same title        |  |
|   |  | <input type="checkbox"/> Duplicate publication |  |
|   |  | <input type="checkbox"/> Plagiarism            |  |
|   |  | <input type="checkbox"/> No                    |  |

## COMMENTS TO AUTHORS

This is an excellent review about the role of phosphodiesterase inhibitors in the management of end-stage heart failure, especially the beneficial effects of combining milrinone infusion and beta-blocker therapy. I have a few minor comments about this manuscript. Please consider the following comments. (Comments) 1. Page 10, lines 2-5 The corrected QT interval was significantly prolonged in the monotherapy group (mean $\pm$  436 $\pm$ 29 msec before vs 469 $\pm$ 28msec after; p=0.002), whereas the interval remained unchanged in the combination group. Most notably, survival at 3 years was 65% higher in the combination group versus the milrinone monotherapy group (p<0.001). Judging from the original article, I think the authors probably make a mistake. Correct "436 $\pm$ 29 msec" to "436 $\pm$ 13 msec". Correct "65%" to "59%".

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Cardiology

**ESPS manuscript NO:** 25170

**Title:** Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure

**Reviewer's code:** 02445850

**Reviewer's country:** Italy

**Science editor:** Xue-Mei Gong

**Date sent for review:** 2016-02-26 14:16

**Date reviewed:** 2016-03-19 04:05

| CLASSIFICATION   | LANGUAGE EVALUATION  | SCIENTIFIC MISCONDUCT                          | CONCLUSION   |
|--|--|--|--|
| <input type="checkbox"/> Grade A: Excellent            | <input checked="" type="checkbox"/> Grade A: Priority publishing     | Google Search:                                 | <input checked="" type="checkbox"/> Accept             |
| <input checked="" type="checkbox"/> Grade B: Very good | <input type="checkbox"/> Grade B: Minor language polishing           | <input type="checkbox"/> The same title        | <input type="checkbox"/> High priority for publication |
| <input type="checkbox"/> Grade C: Good                 | <input type="checkbox"/> Grade C: A great deal of language polishing | <input type="checkbox"/> Duplicate publication | <input type="checkbox"/> Rejection                     |
| <input type="checkbox"/> Grade D: Fair                 | <input type="checkbox"/> Grade D: Rejected                           | <input type="checkbox"/> Plagiarism            | <input type="checkbox"/> Minor revision                |
| <input type="checkbox"/> Grade E: Poor                 |  | [Y] No   | <input type="checkbox"/> Major revision                |
|  |  | BPG Search:                                    |  |
|  |  | <input type="checkbox"/> The same title        |  |
|  |  | <input type="checkbox"/> Duplicate publication |  |
|  |  | <input type="checkbox"/> Plagiarism            |  |
|  |  | [Y] No   |  |

## COMMENTS TO AUTHORS

The authors reviewed the main studies evaluating the use of milrinone in end-stage heart failure. In particular, they focused on the use of milrinone in order to initiate and titrate b-blockers in advanced heart failure. This is a very attractive option, though prospective randomized controlled clinical trials are needed. We congratulate the authors for the comprehensive examination of the role of PDEI agents in end-stage HF. The second case-report raises some questions. The patient received a CRT device. It can be argued that improving clinical status and left ventricular systolic function during follow-up is due mainly to biventricular stimulation rather than milrinone.